Mouse Genome Informatics
cn1
    Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(KRT5-cre/PGR)1Der/?

involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
tumorigenesis
• after RU486 and TPA treatment, 30% of mice develop skin carcinomas compared to 5% of Krastm4Tyj Tg(KRT5-cre/PGR)1Der heterozygotes


Mouse Genome Informatics
cn2
    Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm3Glo
Tg(KRT5-cre/PGR)1Der/?

involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
tumorigenesis
• following treatment with RU486 and TPA, mice develop more tumors than in Krastm4Tyj Trp53tm1Brn/ Trp53tm1Brn Tg(KRT5-cre/PGR)1Der mice
• following treatment with RU486 and TPA, conversion to malignant carcinoma is accelerated relative to in Krastm4Tyj Trp53tm1Brn/ Trp53tm1Brn Tg(KRT5-cre/PGR)1Der mice
• after RU486 and TPA treatment, 60% of tumors that develop are spindle cell carcinomas

homeostasis/metabolism
• following treatment with RU486 and TPA, mice develop more tumors than in Krastm4Tyj Trp53tm1Brn/ Trp53tm1Brn Tg(KRT5-cre/PGR)1Der mice


Mouse Genome Informatics
cn3
    Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT5-cre/PGR)1Der/?

involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
tumorigenesis
• following treatment with RU486 and TPA, mice develop less tumors than in Krastm4Tyj Trp53tm1Brn/Trp53tm3Glo Tg(KRT5-cre/PGR)1Der mice
• after RU486 and TPA treatment, carcinomas that develop following treatment with RU486 and TPA are squamous cell carcinomas with abundant keratin pearls and an absence of spindle cells

homeostasis/metabolism
• following treatment with RU486 and TPA, mice develop less tumors than in Krastm4Tyj Trp53tm1Brn/Trp53tm3Glo Tg(KRT5-cre/PGR)1Der mice


Mouse Genome Informatics
cn4
    Krastm4Tyj/Kras+
Tg(KRT5-cre/PGR)1Der/?

involves: 129/Sv * C57BL/6 * FVB * ICR
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
tumorigenesis
• 7 to 10 weeks after treatment with RU486 to activate the cre transgene, mice develop epidermal papillomas

integument
• 7 to 10 weeks after treatment with RU486 to activate the cre transgene, mice develop epidermal papillomas


Mouse Genome Informatics
cn5
    Krastm4Tyj/Kras+
Trp53tm3Glo/Trp53+
Tg(KRT5-cre/PGR)1Der/?

involves: 129/Sv * C57BL/6 * FVB * ICR
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
tumorigenesis
• after RU486 and TPA treatment, mice develop three-fold more tumors than Krastm4Tyj Trp53tm1Brn heterozygotes and Krastm4Tyj Tg(KRT5-cre/PGR)1Der heterozygotes
• after RU486 and TPA treatment, 60% of mice develop metastasis in the lungs and/or lymph nodes compared to no wild-type mice
• after RU486 and TPA treatment, 42% of tumors exhibit aneuplody compared to 23% of Krastm4Tyj Trp53tm1Brn heterozygotes and 20% of Krastm4Tyj Tg(KRT5-cre/PGR)1Der heterozygotes
• after RU486 and TPA treatment, tumors exhibit centrosome amplification in 3% to 5% of tumors cells
• after RU486 and TPA treatment, carcinoma development is accelerated compared to in Krastm4Tyj Trp53tm1Brn heterozygotes and Krastm4Tyj Tg(KRT5-cre/PGR)1Der heterozygotes
• after RU486 and TPA treatment, 90% of mice develop skin carcinomas compared to 30% of Krastm4Tyj Trp53tm1Brn heterozygotes and 5% of Krastm4Tyj Tg(KRT5-cre/PGR)1Der heterozygotes

homeostasis/metabolism
• after RU486 and TPA treatment, mice develop three-fold more tumors than Krastm4Tyj Trp53tm1Brn heterozygotes and Krastm4Tyj Tg(KRT5-cre/PGR)1Der heterozygotes


Mouse Genome Informatics
cn6
    Dicer1tm1Snj/Dicer1tm1Snj
Tg(KRT5-cre/PGR)1Der/0

involves: 129S7/SvEvBrd * C57BL/6 * FVB * ICR
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
integument
• at 2 to 3 months of age
• at 2 to 3 months of age, mice exhibit a roughening of the epidermis
• cells are larger than in wild-type mice and display a senescence phenotype


Mouse Genome Informatics
cn7
    Tg(KRT5-cre/PGR)1Der/0
Trp63tm2Brd/Trp63tm3.1Brd

involves: 129S7/SvEvBrd * FVB * ICR
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
cellular
• following treatment with mifepristonein in utero, mice exhibit an increase in cellular senescence

craniofacial
• at E17.5 following treatment with mifepristonein in utero

limbs/digits/tail
• at E17.5 following treatment with mifepristonein in utero

growth/size/body
• following treatment with mifepristonein at 8 months of age

skeleton
• following treatment with mifepristonein at 8 months of age, mice exhibit lordokyphosis that increases with severity as mouse ages

integument
• following treatment with mifepristonein at 8 months of age, mice exhibit severe alopecia
• at E17.5 following treatment with mifepristonein in utero or at 8 months of age
• following treatment with mifepristonein utero, mice exhibit stratified epidermal layer and arrested epidermal morphogenesis


Mouse Genome Informatics
cn8
    Krt14tm1Der/Krt14+
Tg(KRT5-cre/PGR)1Der/?

involves: 129X1/SvJ * FVB * ICR
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
integument
• after application of a topical antiprogestin, RU486, to the forelimbs and chest of newborn pups so that the cre transgene translocates from the cytoplasm to the nucleus of epidermal cells and becomes active, mice developed blisters filled with fluid on the front legs and paws
• blistering occurs within the basal layer of the epidermis

Mouse Models of Human Disease
OMIM IDRef(s)
Epidermolysis Bullosa Simplex, Dowling-Meara Type 131760 J:67320